Development of an E. coli-based norbaeocystin production platform and evaluation of behavioral effects in rats
Metabolic Engineering Communications March 11, 2022 Alexandra M. Adams, Nicholas A. Anas, Abhishek K. Sen et al. 21 citations
Interest in the potential therapeutic efficacy of psilocybin and other psychedelic compounds has escalated significantly in recent years. To date, little is known regarding the biological activity of the psilocybin pathway intermediate, norbaeocystin, due to limitations around sourcing the phosphorylated tryptamine metabolite for in vivo testing. To address this limitation, we first developed a...